Piramal Life up on clinical-trial nod

Piramal Life Sciences hit the 5 per cent upper circuit to close the day at Rs 51.50. This was after the firm’s announcement that it has received regulatory approval from the Drug Controller General of India to conduct clinical studies of its cancer molecule P276 for pancreatic, head and neck cancer.

The nod is for phase I/II combination studies of the molecule. The stock opened at the intraday low of Rs 49.10. The scrip made a 52-week high of Rs 519.8 (May 29, 2008) and a low of Rs 30.2 (February 3, 2009).